羟考酮
(+)-纳洛酮
类阿片
医学
麻醉
药理学
内科学
受体
作者
Mairéad Doherty,Hannah Joan Featherstone,Charles A. McAleer,Chloe Webb,Maeve O’Reilly,Marie Twomey,Regina McQuillan
出处
期刊:BMJ supportive & palliative care
[BMJ]
日期:2024-02-26
卷期号:: spcare-004796
标识
DOI:10.1136/spcare-2024-004796
摘要
Combination preparations of oxycodone/naloxone are marketed to aid in the management of opioid induced bowel dysfunction, with caution advised in prescribing in cases of liver dysfunction. This case series demonstrates four cases of patients with normal liver function tests who developed significant opioid toxicity on conversion from combination oxycodone/naloxone to oxycodone at equivalent doses, necessitating significant dose reduction. In each case, a cause for intra-hepatic shunting such as cirrhosis, porto-systemic collaterals or thrombosis were identified, highlighting these as cautionary features when prescribing combination preparations of oxycodone/naloxone and the possible need for dose reduction if converting to oxycodone.
科研通智能强力驱动
Strongly Powered by AbleSci AI